:root { color-scheme: light dark; --frontier:#0A2835; --daylight:#F4F4F4; --linen:#DBD2C4; --catalyst:#FF6700; --slate:#46586A; --mist:#C9D4DC; --ink:#102C38; --muted:#52636c; --paper:#ffffff; --page:#eef1f2; --soft:#f7f8f8; --line:#d6dde0; --positive:#0f7058; --warning:#a64912; --shadow:0 18px 50px rgba(10,40,53,.09); --radius:18px; } @media (prefers-color-scheme: dark) { :root { --ink:#edf5f7; --muted:#b4c2c8; --paper:#102f3d; --page:#08222d; --soft:#123746; --line:#355261; --positive:#79d7bd; --warning:#ffad76; --shadow:0 18px 50px rgba(0,0,0,.28); } } *{box-sizing:border-box} html{scroll-behavior:smooth} body{ margin:0; background:var(--page); color:var(--ink); font-family:Inter, ui-sans-serif, system-ui, -apple-system, BlinkMacSystemFont, "Segoe UI", sans-serif; line-height:1.62; -webkit-font-smoothing:antialiased; } a{color:inherit;text-decoration-color:var(--catalyst);text-decoration-thickness:2px;text-underline-offset:3px} button{font:inherit} .mast{ background:var(--frontier); color:var(--daylight); border-bottom:5px solid var(--catalyst); } .language-bar{max-width:1180px;margin:auto;padding:18px 28px 0;display:flex;justify-content:flex-end} .language-toggle{display:inline-flex;border:1px solid rgba(255,255,255,.35);padding:3px;background:rgba(255,255,255,.08)} .language-toggle button{border:0;background:transparent;color:#dbe6ea;padding:7px 12px;cursor:pointer;font-size:.88rem;font-weight:700} .language-toggle button[aria-pressed="true"]{background:var(--catalyst);color:#1d150f} .language-toggle button:focus-visible{outline:2px solid #fff;outline-offset:2px} .mast-inner{max-width:1180px;margin:auto;padding:28px 28px 48px;display:grid;grid-template-columns:minmax(0,1fr) 310px;gap:56px;align-items:end} .eyebrow{font-size:.82rem;font-weight:700;letter-spacing:.11em;text-transform:uppercase;color:#ffc39e;margin:0 0 14px} h1,h2,h3{font-family:"Source Sans 3", ui-sans-serif, system-ui, sans-serif;letter-spacing:-.025em;margin:0;line-height:1.06} h1{font-size:clamp(2.55rem,6vw,5.35rem);max-width:850px;font-weight:650} .dek{font-size:1.16rem;line-height:1.55;color:#dbe6ea;max-width:790px;margin:24px 0 0} .stamp{border-top:1px solid rgba(255,255,255,.28);padding-top:16px;font-size:.85rem;line-height:1.55;color:#dbe6ea} .stamp strong{display:block;color:#fff;font-size:.98rem;margin-bottom:3px} .page{max-width:1180px;margin:0 auto;padding:0 28px 80px} .answer{ margin:-1px 0 0; display:grid; grid-template-columns:minmax(0,1.5fr) minmax(260px,.5fr); background:var(--paper); box-shadow:var(--shadow); } .answer-main{padding:42px 46px;border-right:1px solid var(--line)} .answer h2{font-size:1rem;text-transform:uppercase;letter-spacing:.08em;color:var(--catalyst);margin-bottom:15px} .answer .lead{font-family:"Source Sans 3",ui-sans-serif,system-ui,sans-serif;font-size:clamp(1.5rem,2.4vw,2.15rem);font-weight:560;line-height:1.3;max-width:800px;margin:0} .answer-side{padding:34px 30px;background:var(--soft)} .answer-side span{font-weight:750;color:var(--catalyst);font-size:2rem;display:block;line-height:1} .answer-side p{margin:10px 0 0;font-size:.96rem} .layout{display:grid;grid-template-columns:240px minmax(0,1fr);gap:56px;margin-top:54px;align-items:start} .rail{position:sticky;top:18px;font-size:.88rem} .rail-title{font-weight:750;margin-bottom:12px;color:var(--muted)} .rail a{display:block;text-decoration:none;border-left:2px solid var(--line);padding:8px 0 8px 16px;color:var(--muted)} .rail a:hover,.rail a:focus{border-left-color:var(--catalyst);color:var(--ink)} .email-card{margin-top:28px;padding:18px;background:var(--frontier);color:#f4f4f4} .email-card strong{font-family:"Source Sans 3",sans-serif;font-size:1.05rem} .email-card p{font-size:.82rem;color:#d9e3e7;line-height:1.5;margin:8px 0 14px} .copy-btn{width:100%;border:0;background:var(--catalyst);color:#1d150f;font-weight:750;padding:10px 12px;cursor:pointer} .copy-btn:hover{filter:brightness(1.07)} article{min-width:0} article h2{font-size:clamp(1.85rem,3.6vw,3rem);margin:70px 0 18px;scroll-margin-top:24px} article h2:first-child{margin-top:0} article h3{font-size:1.35rem;margin:34px 0 10px} article p{font-size:1.05rem;margin:0 0 20px} .intro{font-size:1.2rem;color:var(--muted);max-width:800px} .concepts{display:grid;grid-template-columns:repeat(3,1fr);gap:0;margin:34px 0 28px;border:1px solid var(--line)} .concept{padding:25px 22px;background:var(--paper)} .concept+.concept{border-left:1px solid var(--line)} .concept b{display:inline-grid;place-items:center;width:28px;height:28px;border-radius:50%;background:var(--catalyst);color:#15100d;margin-bottom:13px} .concept strong{display:block;font-family:"Source Sans 3",sans-serif;font-size:1.1rem;line-height:1.25;margin-bottom:8px} .concept p{font-size:.9rem;line-height:1.5;color:var(--muted);margin:0} .country-grid{display:grid;grid-template-columns:repeat(2,minmax(0,1fr));gap:12px;margin:26px 0 36px} .country{padding:18px 20px;background:var(--paper);border-top:3px solid var(--positive)} .country strong{font-family:"Source Sans 3",sans-serif;font-size:1.08rem} .country small{display:block;color:var(--muted);line-height:1.5;margin-top:4px} .country.exception{border-top-color:var(--catalyst)} .country.unverified{border-top-color:var(--warning)} .legend{display:flex;gap:18px;flex-wrap:wrap;color:var(--muted);font-size:.82rem;margin-bottom:18px} .dot{display:inline-block;width:9px;height:9px;border-radius:50%;margin-right:6px;background:var(--positive)} .dot.orange{background:var(--catalyst)}.dot.warn{background:var(--warning)} .comparison{display:grid;grid-template-columns:repeat(3,1fr);gap:14px;margin:26px 0} .lane{background:var(--paper);padding:22px;border-top:4px solid var(--mist)} .lane h3{font-size:1.22rem;margin:0 0 8px} .lane p{font-size:.9rem;color:var(--muted);margin:0} .lane.no{border-top-color:var(--warning)} .lane.yes{border-top-color:var(--catalyst)} .callout{margin:32px 0;background:var(--frontier);color:#f4f4f4;padding:28px 30px;border-left:7px solid var(--catalyst)} .callout h3{margin:0 0 10px;color:#fff} .callout p{margin:0;color:#dfe9ec} .route{display:grid;grid-template-columns:repeat(3,1fr);gap:18px;margin:30px 0} .step{padding:0 0 0 18px;border-left:4px solid var(--catalyst)} .step span{font-size:.78rem;text-transform:uppercase;letter-spacing:.1em;color:var(--muted);font-weight:750} .step strong{display:block;font-family:"Source Sans 3",sans-serif;font-size:1.18rem;line-height:1.25;margin-top:4px} .details{border:1px solid var(--line);background:var(--paper);margin:26px 0} details{border-bottom:1px solid var(--line);padding:0 22px} details:last-child{border-bottom:0} summary{cursor:pointer;font-weight:750;padding:18px 0} details p{font-size:.94rem;color:var(--muted)} .sources{font-size:.9rem;color:var(--muted);background:var(--soft);padding:24px;margin-top:54px} .sources h3{margin:0 0 12px;color:var(--ink)} .sources ul{margin:0;padding-left:20px} .sources li{margin:8px 0} .disclaimer{font-size:.8rem;color:var(--muted);border-top:1px solid var(--line);padding-top:18px;margin-top:32px} .cta{margin:58px 0 0;padding:38px;background:var(--catalyst);color:#1d150f;display:flex;justify-content:space-between;gap:32px;align-items:center} .cta h2{font-size:clamp(1.8rem,3.6vw,2.8rem);margin:0;max-width:700px} .cta p{margin:8px 0 0;max-width:650px} .cta a{background:var(--frontier);color:#fff;text-decoration:none;padding:14px 18px;font-weight:750;white-space:nowrap} .toast{position:fixed;right:20px;bottom:20px;background:var(--frontier);color:#fff;padding:12px 16px;box-shadow:var(--shadow);opacity:0;transform:translateY(10px);transition:.2s;pointer-events:none;font-size:.9rem} .toast.show{opacity:1;transform:none} @media (max-width:850px){ .language-bar{padding:14px 22px 0} .mast-inner{grid-template-columns:1fr;gap:28px;padding:22px 22px 36px} .page{padding:0 18px 56px} .answer{grid-template-columns:1fr} .answer-main{padding:30px 24px;border-right:0;border-bottom:1px solid var(--line)} .answer-side{padding:22px 24px} .layout{grid-template-columns:1fr;gap:0;margin-top:40px} .rail{position:static;margin-bottom:40px} .rail nav{display:grid;grid-template-columns:1fr 1fr} .rail a{padding:7px 12px;border-left:0;border-bottom:1px solid var(--line)} .email-card{margin-top:22px} .concepts,.comparison,.route{grid-template-columns:1fr} .concept+.concept{border-left:0;border-top:1px solid var(--line)} .country-grid{grid-template-columns:1fr} .cta{display:block;padding:28px 24px} .cta a{display:inline-block;margin-top:20px;white-space:normal} } @media (max-width:520px){ h1{font-size:2.45rem} .rail nav{grid-template-columns:1fr} article h2{margin-top:54px} } @media print{ body{background:#fff;color:#111} .mast{background:#0A2835 !important;-webkit-print-color-adjust:exact;print-color-adjust:exact} .rail,.copy-btn,.toast,.language-bar{display:none!important} .layout{display:block} .page{max-width:none} .answer{box-shadow:none} .cta{break-inside:avoid} } .checklist{list-style:none;margin:26px 0 36px;padding:0;counter-reset:step} .checklist li{counter-increment:step;position:relative;padding:16px 18px 16px 58px;background:var(--paper);border:1px solid var(--line);margin:0 0 10px;font-size:.98rem} .checklist li::before{content:counter(step);position:absolute;left:18px;top:16px;width:26px;height:26px;border-radius:50%;background:var(--catalyst);color:#15100d;font-weight:750;font-size:.85rem;display:grid;place-items:center} .byline{font-style:italic;color:var(--muted);font-size:.95rem;margin-top:40px;border-top:1px solid var(--line);padding-top:18px} .ref{font-size:.78em} @media (prefers-reduced-motion:reduce){html{scroll-behavior:auto}.toast{transition:none}}
Medical-device market access · Panama
Panama's registration shortcut — with a catch
Reliance, sequencing, and five lessons from a surgical-robotics filing.
Regulatory snapshot
Reviewed 7 October 2026
Reliance · sequencing · scoping
General information, not legal advice
October 7, 2026
6
min read
By
Julio G. Martinez-Clark, CEO, bioaccess®
The short answer
Panama rewards manufacturers that think in devices, not in portfolios. Its device framework — Law 90/92 implemented by Executive Decree 490, alongside Law 419's classification commission — offers an abbreviated route for products registered in recognized high-standard jurisdictions. But reliance is assessed per device, so each variant needs its own dossier strategy, its own route, and its own filing sequence.
Two laws
Panama runs device market access under Law 90/92 — and Law 419's classification commission can route specific devices into the medicines-law framework.
In this analysis
Reliance: per device, not per company
Add this insight to your email
Copy a concise sponsor-ready paragraph based on the article.
Panama sits in the fast lane for medtech market access in Latin America. Its regulatory framework offers abbreviated routes for products already vetted by high-standard reference regulators, and MINSA's device registration system is built around that reliance logic. But the mechanics are per-device, not per-portfolio — and that distinction is where manufacturers most often get stuck.
The following five lessons come from a recent engagement: a Chinese surgical-robotics manufacturer preparing Panama registration for two device variants. One variant carried a complete home-country file (NMPA registration, EU CE mark, and ANVISA approval). The other had only the CE mark — no home-country registration yet. Same company, same product family, two very different regulatory stories. (Company and device names are withheld for confidentiality.)
1. Which legal regime governs your device?
Medical device registration in Panama is anchored in Law 90 of December 26, 2017 (as amended by Law 92 of September 2, 2019), implemented through Executive Decree 490 of October 4, 2019, with registrations issued by MINSA's Dirección Nacional de Dispositivos Médicos. Alongside it sits Law 419 of February 1, 2024 (amended by Law 462 of March 2025, implemented by Executive Decree 27 of May 2024), which covers medicines and other products for human health and explicitly touches medical devices in certain scopes — including a special classification commission that can route specific devices through the medicines-law framework.
That last point matters in practice: the implementing text of Law 419 provides that where the Special Classification Commission determines a medical device must be regulated under the medicines law, the free-sale-certificate formats of a regulatory authority may be accepted for the device. In other words, the applicable regime — and therefore the dossier you build — can depend on how your device is classified, not just on what it is.
One more moving piece: MINSA put a draft executive decree to newly implement Law 90/92 out for public consultation in early 2026 (comments through February 6, 2026). If you plan Panama filings in 2026, verify the current implementing text before locking a strategy — the details may have changed since this article.
2. Is reliance a per-company pass?
No. Panama's framework provides an abbreviated procedure for products already registered in a country with a high-standard regulatory authority recognized by Panama through executive decree. The current implementing language states it plainly: where the product is registered in such a recognized jurisdiction, registration may follow the abbreviated procedure.
The practical consequence: reliance documents are evaluated per device, not per company. A manufacturer's portfolio does not inherit reliance status as a group. Each variant stands on its own documentary record — its own registration history, its own certificates, its own home-country file. In our engagement, that meant treating the two variants as two separate regulatory exercises from day one, rather than one bundled submission.
For context on how reliance logic plays out across the region, see our map of what an NMPA approval unlocks in Latin America.
3. What happens when one portfolio has two different files?
The first variant arrived with everything: home-country NMPA registration, EU CE mark, and a Brazilian ANVISA approval. That combination gives a registration consultant a clean reliance story — the documentary record maps onto the abbreviated route, and the open questions are administrative (formats, translations, local representation) rather than evidentiary.
The second variant had only the CE mark — no home-country registration yet. That is not a fatal gap, but it is a different filing. The reliance documents differ, the dossier strategy differs, and the sequencing differs. Conflating the two into a single filing plan is the most common mistake we see: the strong file gets dragged down by the incomplete one, or the incomplete one is filed on the back of assumptions drawn from the strong one, and both suffer.
The fix is architectural: scope the CE-only device as its own track, with its own dossier strategy and its own reliance pathway, rather than as a bundled afterthought of the first filing.
4. Which device should file first?
Which device files first shapes the entire market-access timeline. Filing the fully documented variant first does two things: it moves the earliest achievable revenue date forward, and it creates regulatory momentum — an approved registration that the rest of the portfolio strategy can reference.
The CE-only variant then follows on its own track, once its documentation picture is complete enough to support its route. This sequencing also protects the project: if the second track needs additional documentation or a different reliance argument, the first registration is already through. A portfolio filed as one bundle creates one failure point; a sequenced portfolio creates options.
Registration is only half the Panama story — for the clinical-trial side, see our step-by-step guide to running early feasibility studies for medical devices in Panama.
5. How do you phase scope to the budget?
Manufacturers sometimes stall registration work because the quote is presented as one indivisible number. In practice, registration scope is modular: variants can be phased, milestones can be staged, and the work can be aligned to a working budget without abandoning the full plan.
The discipline is to keep the phasing regulatory coherent — each phase still filed under the right route, with the right documents, for the right device — while the commercial packaging flexes. Phase the scope, keep the strategy intact.
The takeaway
Panama rewards manufacturers that think in devices, not in portfolios. Know which legal regime classifies your product. Treat reliance as a per-device question. Give the CE-only variant its own track and its own dossier. Sequence the complete file first. And phase the scope to the budget without diluting the regulatory logic.
Timelines in Panama vary by route and by dossier completeness — any consultant who quotes you a single fixed clock for every device is selling certainty the framework doesn't offer.
Julio G. Martinez-Clark is CEO of bioaccess, a first-in-human CRO running early-stage clinical trials across Latin America.
Frequently asked questions
Which law governs medical device registration in Panama?
Law 90 of December 26, 2017, amended by Law 92 of September 2, 2019, implemented by Executive Decree 490 of October 4, 2019. Registrations are issued by MINSA's Dirección Nacional de Dispositivos Médicos. Law 419 of February 1, 2024 (amended by Law 462 of March 2025, implemented by Executive Decree 27 of May 2024) covers medicines and other health products and can reach medical devices through a Special Classification Commission — so which regime applies can depend on classification.
Does Panama offer an abbreviated registration procedure?
Yes. Where a product is registered in a country with a high-standard regulatory authority recognized by Panama through executive decree, registration may follow the abbreviated procedure. Where the Special Classification Commission routes a device under the medicines law, the free-sale-certificate formats of a regulatory authority may be accepted for it.
Is reliance assessed per company or per device?
Per device. A manufacturer's portfolio does not inherit reliance status as a group — each variant stands on its own registration history, certificates, and home-country file.
Can a CE mark alone anchor a Panama filing?
It depends on the device's classification and documentary record. A CE mark is a dossier asset, but the admissible reliance documents and the applicable route differ from a filing backed by a complete home-country registration. Treat a CE-only variant as its own track with its own dossier strategy.
Should I file my whole device portfolio in one submission?
No. Sequence the fully documented device first — it moves the earliest revenue date forward and creates regulatory momentum — and run other variants as separate tracks with their own routes and timing.
Regulatory instruments referenced
- Law 90 of December 26, 2017 (Panama) — medical devices, as amended by Law 92 of September 2, 2019.
- Executive Decree 490 of October 4, 2019 — implements Law 90/92; registrations issued by MINSA's Dirección Nacional de Dispositivos Médicos.
- Law 419 of February 1, 2024 (Panama) — medicines and other products for human health, as amended by Law 462 of March 18, 2025.
- Executive Decree 27 of May 10, 2024 — implements Law 419/462, including the Special Classification Commission and abbreviated-procedure provisions.
This regulatory snapshot reflects the instruments reviewed as of 7 October 2026. Panama's device framework is under active update; verify the current implementing text, holder requirements, and reliance-document lists with qualified regulatory advisers before filing. General information only, not legal advice.
Plan Panama device-by-device.
bioaccess helps medical-device teams build first-in-human and market-entry programs across Latin America around the evidence they already have — and the approvals they still need.